Mineralys Therapeutics, Inc. (MLYS)
$22.23-4.88%Close
SELLCRISIS · day 12
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.0B
- Beta
- 0.69
- P/E (TTM)
- -5.18
- Short % float
- 12.03%
- Days to cover
- 5.2
- SI change
- -15.0%
- 1W
- -4.59%
- 1M
- -21.17%
- vs SPY 1W
- -5.01%
- vs SPY 1M
- -23.23%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on MLYS?
- LOPJLB’s latest quantitative signal on Mineralys Therapeutics, Inc. (MLYS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is MLYS in?
- Mineralys Therapeutics, Inc. (MLYS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Mineralys Therapeutics, Inc. (MLYS) do?
- Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected…